{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:45:34Z","timestamp":1794185134887,"version":"4.8.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We prove that the SH2-containing tyrosine phosphatase 1 (SHP-1) plays a prominent role as resistance determinant of imatinib (IMA) treatment response in chronic myelogenous leukemia cell lines (sensitive\/KCL22-S and resistant\/KCL22-R). Indeed, SHP-1 expression is significantly lower in resistant than in sensitive cell line, in which coimmunoprecipitation analysis shows the interaction between SHP-1 and a second tyrosine phosphatase SHP-2, a positive regulator of RAS\/MAPK pathway. In KCL22-R SHP-1 ectopic expression restores both SHP-1\/SHP-2 interaction and IMA responsiveness; it also decreases SHP-2 activity after IMA treatment. Consistently, SHP-2 knocking-down in KCL22-R reduces either STAT3 activation or cell viability after IMA exposure. Therefore, our data suggest that SHP-1 plays an important role in BCR-ABL\u2013independent IMA resistance modulating the activation signals that SHP-2 receives from both BCR\/ABL and membrane receptor tyrosine kinases. The role of SHP-1 as a determinant of IMA sensitivity has been further confirmed in 60 consecutive untreated patients with chronic myelogenous leukemia, whose SHP-1 mRNA levels were significantly lower in case of IMA treatment failure (P &lt; .0001). In conclusion, we suggest that SHP-1 could be a new biologic indicator at baseline of IMA sensitivity in patients with chronic myelogenous leukemia.<\/jats:p>","DOI":"10.1182\/blood-2011-03-341073","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T23:55:36Z","timestamp":1312588536000},"page":"3634-3644","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome\u2013positive cells derived from patients with chronic myeloid leukemia"],"prefix":"10.1182","volume":"118","author":[{"given":"Nicola","family":"Esposito","sequence":"first","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Colavita","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Quintarelli","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino Rodeo","family":"Sica","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lucia","family":"Peluso","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Luciano","sequence":"additional","affiliation":[{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Picardi","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Buonomo","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Institute of Medical & Veterinary Science, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"White","sequence":"additional","affiliation":[{"name":"Institute of Medical & Veterinary Science, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Ospedali Civili, Brescia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[{"name":"Institute of Medical & Veterinary Science, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, University at Orbassano, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junia V.","family":"Melo","sequence":"additional","affiliation":[{"name":"Institute of Medical & Veterinary Science, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Martinelli","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Facolt\u00e0 di Medicina e Chirurgia dell' Universit\u00e0 degli Studi di Salerno, Salerno, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Ruoppolo","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Kalebic","sequence":"additional","affiliation":[{"name":"Novartis Oncology Clinical Development, East Hanover, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, L. and A. Seragnoli, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate, Naples, Italy;"},{"name":"Dipartimento di Biochimica\u2013Biotecnologie Mediche, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111807373507200_B1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer.","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2019111807373507200_B2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111807373507200_B3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111807373507200_B4","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111807373507200_B5","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"issue":"20","key":"2019111807373507200_B6","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","article-title":"Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.","volume":"92","author":"Gambacorti-Passerini","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2019111807373507200_B7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"issue":"31","key":"2019111807373507200_B8","doi-asserted-by":"crossref","first-page":"21878","DOI":"10.1074\/jbc.M605018200","article-title":"Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling.","volume":"281","author":"Wang","year":"2006","journal-title":"J Biol Chem"},{"issue":"11","key":"2019111807373507200_B9","first-page":"1251","article-title":"The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.","volume":"22","author":"Chong","year":"2007","journal-title":"Histol Histopathol"},{"issue":"43","key":"2019111807373507200_B10","doi-asserted-by":"crossref","first-page":"41677","DOI":"10.1074\/jbc.M306461200","article-title":"Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors.","volume":"278","author":"Araki","year":"2003","journal-title":"J Biol Chem"},{"issue":"22","key":"2019111807373507200_B11","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1128\/MCB.20.22.8513-8525.2000","article-title":"The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase.","volume":"20","author":"Maroun","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"7","key":"2019111807373507200_B12","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1074\/jbc.M410012200","article-title":"A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation.","volume":"280","author":"Montagner","year":"2005","journal-title":"J Biol Chem"},{"issue":"13","key":"2019111807373507200_B13","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00018-007-6509-0","article-title":"How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?","volume":"64","author":"Edouard","year":"2007","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"2019111807373507200_B14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/scel.1993.1050","article-title":"Structure and function of SH2-domain containing tyrosine phosphatases.","volume":"4","author":"Neel","year":"1993","journal-title":"Semin Cell Biol"},{"issue":"2","key":"2019111807373507200_B15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"issue":"6","key":"2019111807373507200_B16","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2003-09-3287","article-title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.","volume":"103","author":"Loh","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111807373507200_B17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood-2003-11-3876","article-title":"Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.","volume":"104","author":"Tartaglia","year":"2004","journal-title":"Blood"},{"issue":"18","key":"2019111807373507200_B18","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1182\/blood-2008-10-182626","article-title":"Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.","volume":"113","author":"Chan","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111807373507200_B19","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2003-06-2007","article-title":"SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak\/STAT pathway.","volume":"103","author":"Chim","year":"2004","journal-title":"Blood"},{"issue":"22","key":"2019111807373507200_B20","first-page":"6390","article-title":"Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias\/lymphomas.","volume":"62","author":"Oka","year":"2002","journal-title":"Cancer Res"},{"issue":"4","key":"2019111807373507200_B21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0002-9440(10)64629-9","article-title":"Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.","volume":"157","author":"Zhang","year":"2000","journal-title":"Am J Pathol"},{"issue":"9","key":"2019111807373507200_B22","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/sj.leu.2404323","article-title":"Restoration of shp1 expression by 5-AZA-2\u2032-deoxycytidine is associated with downregulation of JAK3\/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.","volume":"20","author":"Han","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2019111807373507200_B23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3346\/jkms.2009.24.3.493","article-title":"Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia.","volume":"24","author":"Uhm","year":"2009","journal-title":"J Korean Med Sci"},{"issue":"4","key":"2019111807373507200_B24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.2178","article-title":"Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.","volume":"212","author":"Amin","year":"2007","journal-title":"J Pathol"},{"issue":"14","key":"2019111807373507200_B25","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1073\/pnas.93.14.6898","article-title":"The stress response to ionizing radiation involves c-Abl-dependent phosphorylation of SHPTP1.","volume":"93","author":"Kharbanda","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2019111807373507200_B26","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/sj.leu.2402214","article-title":"Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation.","volume":"15","author":"Bruecher-Encke","year":"2001","journal-title":"Leukemia"},{"issue":"5","key":"2019111807373507200_B27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein.","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"issue":"35","key":"2019111807373507200_B28","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"45","key":"2019111807373507200_B29","doi-asserted-by":"crossref","first-page":"35631","DOI":"10.1074\/jbc.M005401200","article-title":"c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines.","volume":"275","author":"Brasher","year":"2000","journal-title":"J Biol Chem"},{"issue":"10","key":"2019111807373507200_B30","first-page":"1974","article-title":"Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.","author":"Colavita","year":"1804","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2019111807373507200_B31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0145-2126(86)90088-3","article-title":"Effects of 5-aza-2\u2032-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells.","volume":"10","author":"Chabot","year":"1986","journal-title":"Leuk Res"},{"issue":"1","key":"2019111807373507200_B32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gde.2006.12.011","article-title":"The role of Shp2 (PTPN11) in cancer.","volume":"17","author":"Mohi","year":"2007","journal-title":"Curr Opin Genet Dev"},{"issue":"3","key":"2019111807373507200_B33","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2019111807373507200_B34","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/leu.2008.337","article-title":"Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.","volume":"23","author":"Bruennert","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2019111807373507200_B35","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood-2004-03-1151","article-title":"Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma.","volume":"104","author":"Khoury","year":"2004","journal-title":"Blood"},{"issue":"22","key":"2019111807373507200_B36","doi-asserted-by":"crossref","first-page":"12233","DOI":"10.1073\/pnas.210253497","article-title":"BCR\/ABL inhibition by an escort\/phosphatase fusion protein.","volume":"97","author":"Lim","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2019111807373507200_B37","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/sj.onc.1202117","article-title":"Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase.","volume":"17","author":"Liedtke","year":"1998","journal-title":"Oncogene"},{"issue":"6","key":"2019111807373507200_B38","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0092-8674(95)90277-5","article-title":"Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.","volume":"82","author":"Goga","year":"1995","journal-title":"Cell"},{"issue":"3","key":"2019111807373507200_B39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","article-title":"The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway.","volume":"20","author":"Dance","year":"2008","journal-title":"Cell Signal"},{"issue":"14","key":"2019111807373507200_B40","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","article-title":"Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.","volume":"28","author":"Samanta","year":"2009","journal-title":"Oncogene"},{"issue":"2","key":"2019111807373507200_B41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2006.06161.x","article-title":"BCR-ABL activates STAT3 via JAK and MEK pathways in human cells.","volume":"134","author":"Coppo","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111807373507200_B42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1097-2765(01)00369-0","article-title":"Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling.","volume":"8","author":"Lu","year":"2001","journal-title":"Mol Cell"},{"issue":"13","key":"2019111807373507200_B43","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1096\/fasebj.13.13.1699","article-title":"The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK\/STAT pathway.","volume":"13","author":"Vila-Coro","year":"1999","journal-title":"FASEB J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/13\/3634\/1343540\/zh803911003634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/13\/3634\/1343540\/zh803911003634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:46:05Z","timestamp":1574063165000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/13\/3634\/29263\/SHP1-expression-accounts-for-resistance-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,29]]},"references-count":43,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2011,9,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-341073","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,29]]}}}